Related Experiment Video
Updated: Jun 21, 2025
09:31
Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
10.6K
Correlations between plasma markers and brain Aβ deposition across the AD continuum: Evidence from SILCODE
Xianfeng Yu1,2, Rong Shi3, Xia Zhou2
1Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.
Summary
Alzheimer
Area of Science:
- Neurology
- Biomarker Discovery
- Neurodegenerative Diseases
Background:
- Alzheimer's disease (AD) plasma markers link to amyloid beta (Aβ) deposition.
- The association's changes across Aβ pathological stages are not fully understood.
Purpose of the Study:
- Investigate the relationship between plasma biomarkers and Aβ pathology across different AD stages.
- Clarify the role of plasma markers in early AD, particularly in subjective cognitive decline (SCD).
Main Methods:
- Utilized SILCODE data for correlation and mediation analyses.
- Assessed plasma biomarkers, amyloid PET SUVR, and clinical scales.
- Classified participants based on Aβ stage and cognitive status.
Main Results:
- Plasma phosphorylated tau (p-tau)181 and glial fibrillary acidic protein (GFAP) were lower in early Aβ stages (A0).
- Cognitively normal (CN) and SCD individuals predominated in early Aβ stages (A0-1).
- Mediated effects observed: PET SUVR-plasma p-tau181-MMSE and PET SUVR-plasma GFAP-MMSE.
Conclusions:
- Plasma p-tau181 and GFAP indicate early AD and Aβ pathology staging.
- Confirmed plasma markers' role in early Aβ deposition, especially in females with SCD.
- Identified overlapping brain regions (posterior cingulate, rectus gyrus, inferior temporal) for these markers in early AD.
